Liberty Energy Inc. Class A common stock vs Smith & Nephew plc — how do they compare? Liberty Energy Inc. Class A common stock trades at $19.08 (market cap $3.08B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 3.6× Liberty Energy Inc. Class A common stock's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Liberty Energy Inc. Class A common stock for 1 Days and Smith & Nephew plc for 121 Days on average.
| LBRT | SNN | |
|---|---|---|
Market Cap | $3.08B | $11.10B |
Volume | 4,917,315 | 1,051,703 |
Sector | Energy | Health |
52-Week High | $33.93 | $37.17 |
52-Week Low | $11.94 | $26.42 |
Typical Hold Time | 1 Days | 121 Days |
Enterprise Value | $4.13B | $14.13B |
Dividend Yield | 1.91% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Trailing returns across standard periods
Liberty Energy provides completion services and technologies for onshore oil, natural gas, and geothermal producers in North America. It also offers distributed power and energy-storage solutions through Liberty Power Innovations.
Read more on LBRT →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →